Top Story

TURQUOISE-II: Demographics, viral factors did not predict SVR after 3D regimen

November 21, 2014

BOSTON — Sustained virologic response rates after treatment with an all-oral regimen of coformulated ABT-450 boosted with ritonavir, ombitasvir and dasabuvir plus ribavirin were high in patients with hepatitis C virus genotype 1 infection and cirrhosis across a broad range of subgroups and regardless of baseline characteristics.

Michael W. Fried, MD, professor of medicine and director of the University of North Carolina Liver Center, presented new data from the TURQUOISE-II study at The Liver Meeting.

EMA panel recommends approval of DAA regimen for patients with HCV

November 21, 2014
The European Committee for Medicinal Products for Human Use, or CHMP, granted a positive opinion for the recommendation of Viekirax plus Exviera, with or without…

Commission approves ledipasvir/sofosbuvir combo for marketing in EU

November 20, 2014
The European Commission granted marketing authorization to Gilead Sciences for its once-daily single tablet regimen of Harvoni for the treatment of adults with chronic…
Check Hep C program effective in identifying HCV in New York Meeting News CoveragePerspective

Check Hep C program effective in identifying HCV in New York

November 20, 2014
BOSTON — The Check Hep C program, a community-based initiative in New York that focuses on finding and testing individuals with hepatitis C virus infection in…
CME
HCV Consults: Volume 1, Number 2

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »
Meeting News Coverage Video
thumbnail for video 3895262652001

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared…
More »
CME
HCV Consults 2014

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »
Meeting News Coverage

TURQUOISE-II: Demographics, viral factors did not predict SVR after 3D regimen

November 21, 2014
BOSTON — Sustained virologic response rates after treatment with an all-oral regimen of coformulated ABT-450 boosted with ritonavir, ombitasvir…

EMA panel recommends approval of DAA regimen for patients with HCV

November 21, 2014
The European Committee for Medicinal Products for Human Use, or CHMP, granted a positive opinion for the recommendation of Viekirax plus Exviera…

Commission approves ledipasvir/sofosbuvir combo for marketing in EU

November 20, 2014
The European Commission granted marketing authorization to Gilead Sciences for its once-daily single tablet regimen of Harvoni for the treatment of…
Check Hep C program effective in identifying HCV in New York Meeting News CoveragePerspective

Check Hep C program effective in identifying HCV in New York

November 20, 2014
BOSTON — The Check Hep C program, a community-based initiative in New York that focuses on finding and testing individuals with hepatitis C…
thumbnail for video 3899432251001 Meeting News CoverageVideo

New HCV treatments could reduce mortality, but increase costs by billions

November 19, 2014
BOSTON – In this video exclusive from The Liver Meeting, David B. Rein, PhD, MPA, of the National Opinion Research Center, also known as the…
In the Journals

Anti-HCV prevalence higher in MSM injection drug users vs. nonusers

November 18, 2014
Injection drug-using men who have sex with men had a higher anti-hepatitis C virus prevalence rate compared with men who did not inject drugs…
HAV hospitalization rate decreased in US from 2002 to 2011 In the Journals

HAV hospitalization rate decreased in US from 2002 to 2011

November 18, 2014
Hospitalizations caused by hepatitis A virus infection declined in the United States from 2002 to 2011, recent study data show. “While HAV…
Meeting News Coverage

ALLY 3: Daclatasvir/sofosbuvir combination shows efficacy in HCV genotype 3

November 17, 2014
BOSTON — Combination therapy with daclatasvir and sofosbuvir was associated with an 12-week sustained virologic response rate of 90% in…
thumbnail for video 3895262652001 Meeting News CoverageVideo

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared patients with alcoholic…
Meeting News Coverage

Two studies show promise for 8-week treatment with GS-5816

November 14, 2014
BOSTON — Pangenotypic NS5A inhibitor GS-5816 in combination with sofosbuvir-containing regimens demonstrated encouraging results in a number of…
More Headlines »
morganatic-roan
morganatic-roan